05:10 AM EDT, 09/19/2024 (MT Newswires) -- Scisparc ( SPRC ) said late Wednesday it has submitted an investigational new drug application to the US Food and Drug Administration for a phase 2b trial of SCI-110 as potential treatment of Tourette Syndrome.

The company said it has already secured approvals to test the drug's efficacy, safety and tolerability at sites in the US, Germany and Israel.